Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Fragile X Syndrome
NCT04141163Phase 2Unknown
- Sponsor
- Rowan University
- Start
- Oct 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liquid metformin (Aspargo Labs) in Fragile X syndrome (FXS) (2 arms), sponsored by Rowan University. Primary endpoint: Safety and tolerability of metformin at 24 weeks. Status: unknown.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT04141163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04141163.